Behshad Shadi, Mohammadi Yaser, Sarab Gholamreza Anani, Malekaneh Mohammad, Farimani Azam Rezaei
Department of Biochemistry, Faculty of Medicine Birjand University of Medical Sciences Birjand Iran.
Student Research Committee Iran University of Medical Sciences Tehran Iran.
Health Sci Rep. 2025 Apr 29;8(5):e70770. doi: 10.1002/hsr2.70770. eCollection 2025 May.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and chronic inflammation. The activation of the NLRP3 inflammasome is a key contributor to the inflammatory processes associated with T2DM, which can exacerbate disease progression. This study aims to evaluate the effects of vitamin D3 supplementation on oxidative stress markers and NLRP3 gene expression in patients with T2DM.
Sixty-eight patients with T2DM, exhibiting HbA1c levels greater than 6.5% and serum 25(OH) vitamin D3 levels below 30 ng/mL, were enrolled in this randomized controlled trial. Participants were assigned to either a vitamin D3 group ( = 34), receiving 50,000 IU/week for 8 weeks, or a placebo group ( = 34). Serum levels of oxidative stress markers (malondialdehyde [MDA], total antioxidant capacity [TAC], and thiol levels) and NLRP3 gene expression were assessed at baseline and after the intervention.
The vitamin D3 group demonstrated a significant increase in serum 25(OH) vitamin D3 levels compared to the placebo group ( < 0.001). However, no significant changes were observed in oxidative stress markers (MDA, TAC, and thiol levels) between the groups. Importantly, NLRP3 gene expression was significantly reduced in the vitamin D3 group compared to the placebo group ( < 0.02).
These findings suggest that vitamin D3 supplementation may effectively reduce inflammation in T2DM patients by lowering NLRP3 expression. This supports the potential role of vitamin D3 as an adjunctive therapy for managing inflammation and oxidative stress in individuals with T2DM.
2型糖尿病（T2DM）是一种以胰岛素抵抗和慢性炎症为特征的慢性代谢紊乱疾病。NLRP3炎性小体的激活是与T2DM相关的炎症过程的关键促成因素，可加剧疾病进展。本研究旨在评估补充维生素D3对T2DM患者氧化应激标志物和NLRP3基因表达的影响。
本随机对照试验纳入了68例T2DM患者，其糖化血红蛋白（HbA1c）水平大于6.5%且血清25（OH）维生素D3水平低于30 ng/mL。参与者被分配到维生素D3组（n = 34），接受每周50,000 IU，共8周，或安慰剂组（n = 34）。在基线和干预后评估氧化应激标志物（丙二醛[MDA]、总抗氧化能力[TAC]和巯基水平）的血清水平以及NLRP3基因表达。
与安慰剂组相比，维生素D3组血清25（OH）维生素D3水平显著升高（P < 0.001）。然而，两组之间氧化应激标志物（MDA、TAC和巯基水平）未观察到显著变化。重要的是，与安慰剂组相比，维生素D3组NLRP3基因表达显著降低（P < 0.02）。
这些发现表明，补充维生素D3可能通过降低NLRP3表达有效减轻T2DM患者的炎症。这支持了维生素D3作为辅助治疗在管理T2DM个体炎症和氧化应激方面的潜在作用。
